CD274 and neoplasm: In comparison with the preclinical protocol (24 Gy in 3 fractions) and previous studies,[6, 10, 14] the significantly lower dose RT (6 Gy in 3 fractions) in our study simultaneously achieved the reconstruction of the tumor immuno‐microenvironment and the reinforcement of anti‐PD‐L1 therapy while further avoiding the adverse effects, because of the above advantages of the BMS202@HZP NPs (Figure 1a,c).